Baird lowered the firm’s price target on Zimmer Biomet (ZBH) to $130 from $138 and keeps an Outperform rating on the shares. The firm said steady progress continues even if it is masked in the short-term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Reports Strong 2024 Financial Performance
- ZBH Upcoming Earnings Report: What to Expect?
- Starbucks reports Q1 beat, Frontier proposes Spirit combination: Morning Buzz
- BofA moves to No Rating on Paragon 28 after Zimmer Biomet deal
- Treace Medical ‘a rarer asset’ after Zimmer buys Paragon 28, says Lake Street